The retinal physiology can accrue oxidative damage and inflammatory insults due to age and metabolic irregularities. Two notable diseases that involve retinal and choroidal neovascularization are proliferative diabetic retinopathy and wet age-related macular degeneration. Currently, these diseases are mainly treated with anti-VEGF drugs (VEGF = vascular endothelial growth factor), generally on a monthly dosage scheme. We discuss recent developments for the treatment of these diseases, including bioactive tissue-engineered materials, which may reduce frequency of dosage and propose a path forward for improving patient outcomes. [Figure not available: see fulltext.].
- Age-related macular degeneration
- Anti-angiogenic materials
- Diabetic retinopathy
- Pathological neovascularization
- Peptide nanofibers
ASJC Scopus subject areas
- Pharmaceutical Science